Podcast on the Management of Adverse Events Associated with Lorlatinib

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer· 2020 · 1,052 citations
2. Clinical Management of Adverse Events Associated with Lorlatinib· 2019 · 162 citations
3. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer· 2016 · 195 citations
4. Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations· 2014 · 581 citations
5. Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC· 2021 · 55 citations